Skip to main content

Advertisement

SpringerLink
Log in

Systemic Therapy for Inoperable and Metastatic Basal Cell Cancer

  • Skin Cancer (WH Sharfman, Section Editor)
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion Statement

Cutaneous basal cell carcinoma (BCC) is the most common human malignancy. The majority of cases are cured with local therapies and advanced disease is quite rare. However, locally advanced (inoperable) and metastatic basal cell carcinoma may occur more often than previously thought. Surgery, and other local therapies, is the primary treatment for BCC. However, some resections can be extensive and carry significant morbidity or disfigurement. The prognosis for locally advanced and metastatic BCC is quite poor, and cytotoxic chemotherapies offer limited benefit. Aberrations in the sonic hedgehog (HH) signaling pathway are common in BCC. Novel molecular therapies targeted against this pathway, such as vismodegib (GDC-0449), have shown dramatic activity in advanced basal cell carcinoma. The role of these in nevoid basal cell carcinoma syndrome (Gorlin) syndrome is still under investigation. However, systemic therapies are not curative and require long-term treatment and should not be used in place of curative procedures. Evaluation by experienced physicians and/or by a multidisciplinary tumor board for possible curative/definitive surgery with or without radiation is recommended before initiation of systemic therapy. Clinical trial enrollment also is recommended. Comorbid conditions as well as social circumstances may be factors when deciding on an optimal therapy, in particular with oral agents. Patients treated with HH pathway inhibitors require regular physician monitoring to assess for side effects, benefit, and compliance. Patients of child-bearing potential must be strongly counseled regarding the risk of birth defects and need for birth control. Primary and secondary resistance to HH pathway inhibitors is only beginning to be described.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Rogers HW, Weinstock MA, Harris AR, et al. Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol. 2010;146(3):283–7.

    Article  PubMed  Google Scholar 

  2. Rubin AI, Chen EH, Ratner D. Basal-cell carcinoma. N Engl J Med. 2005;353(21):2262–9.

    Article  PubMed  CAS  Google Scholar 

  3. Silverman MK, Kopf AW, Grin CM, et al. Recurrence rates of treated basal cell carcinomas. Part 1: overview. J Dermatol Surg Oncol. 1991;17(9):713–8.

    PubMed  CAS  Google Scholar 

  4. Gallagher RP, Hill GB, Bajdik CD, et al. Sunlight exposure, pigmentary factors, and risk of nonmelanocytic skin cancer. I. Basal cell carcinoma. Arch Dermatol. 1995;131:157–63.

    Article  PubMed  CAS  Google Scholar 

  5. Zhang M, Qureshi AA, Geller AC, et al. Use of tanning beds and incidence of skin cancer. J Clin Oncol. 2012;30(14):1588–93. Large cohort study that showed a dose–response relationship between indoor tanning and skin cancer, strongest for BCC.

    Article  PubMed  Google Scholar 

  6. Lear JT, Tan BB, Smith AG, et al. Risk factors for basal cell carcinoma in the UK: case–control study in 806 patients. J R Soc Med. 1997;90(7):371–4.

    PubMed  CAS  Google Scholar 

  7. Wilkins K, Turner R, Dolev JC, et al. Cutaneous malignancy and human immunodeficiency virus disease. J Am Acad Dermatol. 2006;54:189–206.

    Article  PubMed  Google Scholar 

  8. Tessari G, Girolomoni G. Nonmelanoma skin cancer in solid organ transplant recipients: update on epidemiology, risk factors and management. Derm Surg. 2012;38(10):1622–30.

    Article  CAS  Google Scholar 

  9. Karagas MR, McDonald JA, Greenberg ER, et al. Risk of basal cell and squamous cell skin cancers after ionizing radiation therapy. For the skin cancer prevention study group. J Natl Cancer Inst. 1996;88(24):1848–53.

    Article  PubMed  CAS  Google Scholar 

  10. Castori M, Morrone A, Kanitakis J, et al. Genetic skin diseases predisposing to basal cell carcinoma. Eur J Dermatol. 2012;22(3):299–309.

    PubMed  Google Scholar 

  11. Gorlin RJ. Nevoid basal-cell carcinoma syndrome. Medicine. 1987;66:98–113.

    Article  PubMed  CAS  Google Scholar 

  12. Gorlin RJ. Nevoid basal cell carcinoma syndrome. Dermatol Clin. 1995;13:113–25.

    PubMed  CAS  Google Scholar 

  13. Gailani MR, Bale SJ, Leffell DJ, et al. Developmental defects in Gorlin syndrome related to a putative tumor suppressor gene on chromosome 9. Cell. 1992;69(1):111–7.

    Article  PubMed  CAS  Google Scholar 

  14. Hahn H, Wicking C, Zaphiropoulous PG, et al. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell. 1996;85:841–51.

    Article  PubMed  CAS  Google Scholar 

  15. Johnson RL, Rothman AL, Xie J, et al. Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science. 1996;272:1668–71.

    Article  PubMed  CAS  Google Scholar 

  16. Lin TL, Matsui W. Hedgehog pathway as a drug target: smoothened inhibitors in development. OncoTargets Ther. 2012;5:47–58.

    Article  CAS  Google Scholar 

  17. Aszterbaum M, Rothman A, Johnson RL, et al. Identification of mutations in the human PATCHED gene in sporadic basal cell carcinomas and in patients with the basal cell nevus syndrome. J Invest Dermatol. 1998;110:885–8.

    Article  PubMed  CAS  Google Scholar 

  18. Wolter M, Reifenberger J, Sommer C, et al. Mutations in the human homologue of the Drosophila segment polarity gene patched (PTCH) in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Cancer Res. 1997;57(13):2581–5.

    PubMed  CAS  Google Scholar 

  19. Xie J, Murone M, Luoh SM, et al. Activating smoothened mutations in sporadic basal-cell carcinoma. Nature. 1998;391(6662):90–2.

    Article  PubMed  CAS  Google Scholar 

  20. Ling G, Ahmadian A, Persson A, et al. PATCHED and p53 gene alterations in sporadic and hereditary basal cell cancer. Oncogene. 2001;20:7770–8.

    Article  PubMed  CAS  Google Scholar 

  21. Reifenberger J, Wolter M, Knobbe CB, et al. Somatic mutations in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal cell carcinomas. Br J Dermatol. 2005;152(1):43–51.

    Article  PubMed  CAS  Google Scholar 

  22. Weinstock MA, Bogaars HA, Ashley M, et al. Nonmelanoma skin cancer mortality: a population-based study. Arch Dermatol. 1991;127:1194–7.

    Article  PubMed  CAS  Google Scholar 

  23. Zoccali G, Pajand R, Papa P, et al. Giant basal cell carcinoma of the skin: literature review and personal experience. J Eur Acad Dermatol Venereol. 2012;26(8):942–52.

    Article  PubMed  CAS  Google Scholar 

  24. Ionescu DN, Arida M, Jukic D. Metastatic basal cell carcinoma: four case reports, review of literature, and immunohistochemical evaluation. Arch Pathol Lab Med. 2006;130:45–51.

    PubMed  Google Scholar 

  25. Menz J, Sterrett G, Wall L. Metastatic basal cell carcinoma associated with a small primary tumour. Australas J Dermatol. 1985;26:121–4.

    Article  PubMed  CAS  Google Scholar 

  26. Farasat S, Yu SS, Neel VA, et al. A new American Joint Committee on Cancer staging system for cutaneous squamous cell carcinoma: creation and rationale for inclusion of tumor (T) characteristics. J Am Acad Dermatol. 2011;64(6):1051–9.

    Article  PubMed  Google Scholar 

  27. Paver K, Poyzer K, Burry N, et al. Letter: the incidence of basal cell carcinoma and their metastases in Australia and New Zealand. Australas J Dermatol. 1973;14:53.

    Article  PubMed  CAS  Google Scholar 

  28. Mikhail GR, Nims LP, Kelly Jr AP, et al. Metastatic basal cell carcinoma: review, pathogenesis, and report of two cases. Arch Dermatol. 1977;113:1261–9.

    Article  PubMed  CAS  Google Scholar 

  29. von Domarus H, Stevens PJ. Metastatic basal cell carcinoma: report of five cases and review of 170 cases in the literature. J Am Acad Dermatol. 1984;10:1043–60.

    Article  Google Scholar 

  30. Lo JS, Snow SN, Reizner GT, et al. Metastatic basal cell carcinoma: report of twelve cases with a review of the literature. J Am Acad Dermatol. 1991;24:715–9.

    Article  PubMed  CAS  Google Scholar 

  31. Snow SN, Sahl W, Lo JS, et al. Metastatic basal cell carcinoma: report of five cases. Cancer. 1994;73:328–35.

    Article  PubMed  CAS  Google Scholar 

  32. Lattes R, Kessler RW. Metastasizing basal cell epithelioma of the skin: report of two cases. Cancer. 1951;4:866–78.

    Article  PubMed  CAS  Google Scholar 

  33. Niederkohr RD, Gamie SH. F-18 FDG PET as an imaging tool for detecting and staging metastatic basal cell carcinoma. Clin Nucl Med. 2007;32:491–2.

    Article  PubMed  Google Scholar 

  34. Raszewski RL, Guyuron B. Long-term survival following nodal metastases from basal cell carcinoma. Ann Plast Surg. 1990;24:170–5.

    Article  PubMed  CAS  Google Scholar 

  35. Ko CB, Walton S, Keczkes K. Extensive and fatal basal cell carcinoma: a report of three cases. Br J Dermatol. 1992;127:164–7.

    Article  PubMed  CAS  Google Scholar 

  36. Kovarik C, Stewart D, Barnard JJ. Lethal basal cell carcinoma secondary to cerebral invasion. J Am Acad Dermatol. 2005;52:149–51.

    Article  PubMed  Google Scholar 

  37. Walling HW, Fosko SW, Geraminejad PA, et al. Aggressive basal cell carcinoma: presentation, pathogenesis, and management. Cancer Metastasis Rev. 2004;23(3–4):389–402.

    Article  PubMed  Google Scholar 

  38. Siegle RJ, Wood T. Nonrecurrent primary basal cell carcinoma of the lower extremity with late metastasis. J Dermatol Surg Oncol. 1994;20(7):490–3.

    PubMed  CAS  Google Scholar 

  39. Silverman MK, Kopf AW, Bart RS, et al. Recurrence rates of treated basal cell carcinomas. Part 3: surgical excision. J Dermatol Surg Oncol. 1992;18(6):471–6.

    PubMed  CAS  Google Scholar 

  40. Silverman MK, Kopf AW, Grin CM, et al. Recurrence rates of treated basal cell carcinomas. Part 2: curettage-electrodesiccation. J Dermatol Surg Oncol. 1991;17(9):720–6.

    PubMed  CAS  Google Scholar 

  41. Mulayim N, Silver DF, Ocal IT. Vulvar basal cell carcinoma: two unusual presentations and review of the literature. Gynecol Oncol. 2002;85:532–7.

    Article  PubMed  Google Scholar 

  42. Kinoshita R, Yamamoto O, Yasuda H, et al. Basal cell carcinoma of the scrotum with lymph node metastasis: report of a case and review of the literature. Int J Dermatol. 2005;44(1):54–6.

    Article  PubMed  CAS  Google Scholar 

  43. Dixon AY, Lee SH, McGregor DH. Histologic features predictive of basal cell carcinoma recurrence: results of a multivariate analysis. J Cutan Pathol. 1993;20(2):137–42.

    Article  PubMed  CAS  Google Scholar 

  44. Miller S, Alam M, Anderson J, et al. Basal cell and squamous cell skin cancers. NCCN clinical practice guidelines in oncology. Version 2.2012.

  45. Brown CI, Perry AE. Incidence of perineural invasion in histologically aggressive types of basal cell carcinoma. Am J Dermatopathol. 2000;22:123–5.

    Article  PubMed  CAS  Google Scholar 

  46. Farmer ER, Helwig EB. Metastatic basal cell carcinoma: a clinicopathologic study of seventeen cases. Cancer. 1980;46:748–57.

    Article  PubMed  CAS  Google Scholar 

  47. Healy E, Angus B, Lawrence CM, et al. Prognostic value of Ki67 antigen expression in basal cell carcinomas. Br J Dermatol. 1995;133:737–41.

    Article  PubMed  CAS  Google Scholar 

  48. Bolshakov S, Walker CM, Strom SS, et al. p53 mutations in human aggressive and nonaggressive basal and squamous cell carcinomas. Clin Cancer Res. 2003;9:228–34.

    PubMed  CAS  Google Scholar 

  49. Bath-Hextall FJ, Perkins W, Bong J, et al. Interventions for basal cell carcinoma of the skin. Cochrane Database Syst Rev. 2007;24(1):CD003412.

    Google Scholar 

  50. Silverman MK, Kopf AW, Gladstein AH, et al. Recurrence rates of treated basal cell carcinomas. Part 4: X-ray therapy. J Dermatol Surg Oncol. 1992;18(7):549–54.

    PubMed  CAS  Google Scholar 

  51. Veness MJ. The important role of radiotherapy in patients with non-melanoma skin cancer and other cutaneous entities. J Med Imaging Radiat Oncol. 2008;52(3):278–86.

    Article  PubMed  CAS  Google Scholar 

  52. Hartman R, Hartman S, Green N. Long-term survival following bony metastases from basal cell carcinoma. report of a case. Arch Dermatol. 1986;122:912–4.

    Article  PubMed  CAS  Google Scholar 

  53. Salem P, Hall SW, Benjamin RS, et al. Clinical phase I-II study of cis-dichloro-diammineplatinum(II) given by continuous IV infusion. Cancer Treat Rep. 1978;62:1553–5.

    PubMed  CAS  Google Scholar 

  54. Woods RL, Stewart JF. Metastatic basal cell carcinoma: report of a case responding to chemotherapy. Postgrad Med J. 1980;56:272–3.

    Article  PubMed  CAS  Google Scholar 

  55. Wieman TJ, Shively EH, Woodcock TM. Responsiveness of metastatic basal-cell carcinoma to chemotherapy. a case report. Cancer. 1983;52:1583–5.

    Article  PubMed  CAS  Google Scholar 

  56. Khandekar JD. Complete response of metastatic basal cell carcinoma to cisplatin chemotherapy: a report on two patients. Arch Dermatol. 1990;126(12):1660.

    Article  PubMed  CAS  Google Scholar 

  57. Guthrie Jr TH, McElveen LJ, Porubsky ES, et al. Cisplatin and doxorubicin. An effective chemotherapy combination in the treatment of advanced basal cell and squamous carcinoma of the skin. Cancer. 1985;55(8):1629–32.

    Article  PubMed  Google Scholar 

  58. Guthrie Jr TH, Porubsky ES, Luxenberg MN, et al. Cisplatin-based chemotherapy in advanced basal and squamous cell carcinomas of the skin: results in 28 patients including 13 patients receiving multimodality therapy. J Clin Oncol. 1990;8(2):342–6.

    PubMed  Google Scholar 

  59. Pfeiffer P, Hansen O, Rose C. Systemic cytotoxic therapy of basal cell carcinoma. A review of the literature. Eur J Cancer. 1990;26:73–7.

    Article  PubMed  CAS  Google Scholar 

  60. Moeholt K, Aagaard H, Pfeiffer P, et al. Platinum-based cytotoxic therapy in basal cell carcinoma – a review of the literature. Acta Oncol. 1996;35:677–82.

    Article  PubMed  CAS  Google Scholar 

  61. Jefford M, Kiffer JD, Somers G, et al. Metastatic basal cell carcinoma: rapid symptomatic response to cisplatin and paclitaxel. ANZ J Surg. 2004;74:704–5.

    Article  PubMed  Google Scholar 

  62. Carneiro BA, Watkin WG, Mehta UK, et al. Metastatic basal cell carcinoma: complete response to chemotherapy and associated pure red cell aplasia. Cancer Investig. 2006;24(4):396–400.

    Article  Google Scholar 

  63. Krahn G, Leiter U, Kaskel P, et al. Coexpression patterns of EGFR, HER2, HER3 and HER4 in non-melanoma skin cancer. Eur J Cancer. 2001;37:251–9.

    Article  PubMed  CAS  Google Scholar 

  64. Muller H, Eisendle K, Gastl G, et al. Palliative therapy of giant basal cell carcinoma with the monoclonal anti-epidermal growth factor receptor antibody cetuximab. Br J Dermatol. 2008;158:1386–8.

    Article  PubMed  CAS  Google Scholar 

  65. Caron J, Dereure O, Kerob D, et al. Metastatic basal cell carcinoma: a report of two cases treated with cetuximab. Br J Dermatol. 2009;161:702–3.

    Article  PubMed  CAS  Google Scholar 

  66. Kalapurakal SJ, Malone J, Robbins KT, et al. Cetuximab in refractory skin cancer treatment. J Cancer. 2012;3:257–61.

    Article  PubMed  CAS  Google Scholar 

  67. Chen JK, Taipale J, Cooper MK, et al. Inhibition of hedgehog signaling by direct binding of cyclopamine to smoothened. Genes Dev. 2002;16:2743–8.

    Article  PubMed  CAS  Google Scholar 

  68. Keeler RF. Cyclopamine and related steroidal alkaloid teratogens: their occurrence, structural relationship, and biologic effects. Lipids. 1978;13(10):708–15.

    Article  PubMed  CAS  Google Scholar 

  69. Robarge KD, Brunton SA, Castanedo GM, et al. GDC-0449-a potent inhibitor of the hedgehog pathway. Bioorg Med Chem Lett. 2009;19:5576–81.

    Article  PubMed  CAS  Google Scholar 

  70. Ding X, Chou B, Graham RA, et al. Determination of GDC-0449, a small molecule inhibitor of the Hedgehog signaling pathway, in human plasma by solid phase extraction liquid chromatographic-tandem mass spectrometry. J Chromatogr B. 2010;878:785–90.

    Article  CAS  Google Scholar 

  71. Von Hoff DD, LoRusso PM, Rudin CM, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med. 2009;361:1164–72. Report of the BCC patient cohort treated on the phase I study of the first-in class SMO inhibitor, vismodegib, demonstrating good tolerability and significant clinical activity in advanced BCC.

    Article  Google Scholar 

  72. LoRusso PM, Rudin CM, Reddy JC, et al. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res. 2011;17:2502–11. Report of the entire phase I study of vismodegib with updated efficacy data.

    Article  PubMed  CAS  Google Scholar 

  73. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16.

    Article  PubMed  CAS  Google Scholar 

  74. Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366:2171–9. Pivotal phase II study that evidenced responses in laBCC and mBCC to treatment with vismodegib in advanced BCC, including 21 % CR in laBCC.

    Article  PubMed  CAS  Google Scholar 

  75. Tang JY, Mackay-Wiggan JM, Aszterbaum M, et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med. 2012;366:2180–8. Phase II randomized, double-blind, placebo-controlled study of vismodegib in patients with NBCCS that demonstrated significant decrease in the development of new resectable BCCs as well as decrease in size of existing BCC. Of note, 54 % of patients came off study for toxicity.

    Article  PubMed  CAS  Google Scholar 

  76. Tawbi HA, Rodon Ahnert J, Dummer R, et al. Phase I study of LDE225 in advanced solid tumors: Updated analysis of safety, preliminary efficacy, and pharmacokinetic-pharmacodynamic correlation. J Clin Oncol 2011, 29. (suppl; abstr 3062).

  77. Skvara H, Kalthoff F, Meingassner JG, et al. Topical treatment of Basal cell carcinomas in nevoid Basal cell carcinoma syndrome with a smoothened inhibitor. J Investig Dermatol. 2011;131(8):1735–44. Small study of topical LDE225 that demonstrated both partial and complete regression of primary BCCs in patients with NBCCS with no adverse events.

    Article  PubMed  CAS  Google Scholar 

  78. Rudin CM, Jimeno A, Miller WH, et al. A phase I study of IPI-926, a novel hedgehog pathway inhibitor, in patients (pts) with advanced or metastatic solid tumors. J Clin Oncol 2011, 29. (suppl; abstr 3014).

  79. Siu LL, Papadopoulos N, Alberts SR, et al. A first-in-human, phase I study of an oral hedgehog (HH) pathway antagonist, BMS-833923 (XL139), in subjects with advanced or metastatic solid tumors. J Clin Oncol. 2010;28:15s. suppl; abstr 2501.

    Article  Google Scholar 

  80. Wolfe CM, Green WH, Cognetta Jr AB, et al. Basal cell carcinoma rebound after cessation of vismodegib in a nevoid basal cell carcinoma syndrome patient. Dermatol Surg. 2012;38(11):1863–6.

    Article  PubMed  CAS  Google Scholar 

  81. Rudin CM, Hann CL, Laterra J, et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med. 2009;361:1173–8. First report of acquired resistance to treatment with a SMO inhibitor.

    Article  PubMed  CAS  Google Scholar 

  82. Yauch RL, Dijkgraaf GJ, Alicke B, et al. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science. 2009;326:572–4. Detailed translational report of acquisition of a novel SMO mutation as a possible mechanism of resistance to vismodegib and in vitro data to suggest this is may be due to alterations in drug binding.

    Article  PubMed  CAS  Google Scholar 

  83. Chang AL, Oro AE. Initial assessment of tumor regrowth after vismodegib in advanced basal cell carcinoma. Arch Dermatol. 2012;148(11):1324–5.

    PubMed  Google Scholar 

  84. Rudin CM. Vismodegib. Clin Ca Res. 2012;18(12):3218–22.

    Article  CAS  Google Scholar 

  85. Dijkgraaf GJ, Alicke B, Weinmann L, et al. Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance. Cancer Res. 2011;71:435–44. Important translational article detailing possible mechanisms of resistance to SMO inhibitors and exploring second generation SMO inhibitors in vitro.

    Article  PubMed  CAS  Google Scholar 

  86. Buonamici S, Williams J, Morrissey M, et al. Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Sci Transl Med. 2010;2:51–70. Concurrent translational work exploring multiple possible mechanisms of resistance to SMO inhibitors and combinatorial therapy in vitro.

    Article  Google Scholar 

  87. Kim J, Tang JY, Gong R, et al. Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth. Cancer Cell. 2010;17:388–99.

    Article  PubMed  CAS  Google Scholar 

  88. Lauth M, Bergstrom A, Shimokawa T, et al. Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists. Proc Natl Acad Sci U S A. 2007;104:8455–60.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflicts of Interest

Leslie A. Fecher is a consultant/advisory Board member for Genentech-Roche (compensated) and consultant for Bristol Myers Squibb (uncompensated), received honoraria from Dava Oncology, received honoraria from Imedex and had travel/accommodations expenses covered or reimbursed by Genentech and Roche, and has clinical trial support from Sanofi-Aventis, Genentech-Roche.

Author information

Authors and Affiliations

  1. Hematology-Oncology, Indiana University Health Simon Cancer Center, 535 Barnhill Drive, RT-473, Indianapolis, IN, 46202, USA

    Leslie A. Fecher MD

Authors
  1. Leslie A. Fecher MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Leslie A. Fecher MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fecher, L.A. Systemic Therapy for Inoperable and Metastatic Basal Cell Cancer. Curr. Treat. Options in Oncol. 14, 237–248 (2013). https://doi.org/10.1007/s11864-013-0233-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-013-0233-9

Keywords

Search

Navigation